News / Blog
New Year Holidays 2024 / 2025
Catalog
Ceredist tablets 5 mg for ataxia (muscle movement disorder)
Product Code :
Availability : 7
USD 699.00
General information on Japanese tablets Ceredist 5 mg for ataxia (muscle movement disorder)
Package details: 28 tablets
Manufacturer: Mitsubishi Tanabe Pharma, Japan
Active ingredient: taltirelin hydrate 5 mg (chemical formula C17H31N7O9)
Medical effect: Ceredist tablets improve symptoms of ataxia (muscle movement disorder) caused by spinocerebellar dysfunction. Such symptoms include:
- movement discoordination,
- gait abnormality,
- speech changes,
- abnormalities in eye movements and others.
Contraindications and precautions: do not use in children, pregnant or breastfeeding women. If allergic reaction occurs, stop using the product and consult with your doctor.
Dosage and administration of Japanese tablets Ceredist 5 mg for ataxia (muscle movement disorder)
Take 1 tablet 2 times a day, after breakfast and dinner. The consulting doctor may adjust the dose due to age and symptoms.
About the effects and trials of Ceredist tablets 5 mg for ataxia (muscle movement disorder) from Japan
Japanese tablets Ceredist 5 mg are effective for treatment of the ataxia (muscle movement disorder). Each tablet contains 5 mg of taltirelin hydrate, a mimetic agent of thyrotropin-releasing hormone. This hormone helps to fight with depression, memory impairment, motor disturbances and loss of consciousness. But it’s not very effective to use it directly due to hormone’s rapid metabolic degradation. In other words, the effect doesn’t last long enough.
Taltirelin hydrate has a similar structure to the hormone, but it’s eight times long-lasting when compared to the hormone (K. Kinoshita, M. Yamamura et al. Taltirelin Hydrate (TA-0910): An Orally Active Thyrotropin-Releasing Hormone Mimetic Agent with Multiple Actions. CNS Drug Reviews, June 2006, 4(1): 25-41). Taltirelin promotes the release of neurotransmitters in brain and acts nerve growth factor as well. As a result, it significantly improves symptoms of ataxia in spinocerebellar degeneration, such as movement discoordination, gait abnormality, speech changes, abnormalities in eye movements and others.